NCT01764464View on ClinicalTrials.gov

GRASSP: Gralise® for Spine Surgery Pain

PHASE4CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

March 31, 2016

Study Completion Date

April 30, 2016

Conditions
Post-laminectomy Pain Syndrome
Interventions
DRUG

Gralise®

14 day titration (days 1-7 at 600 mg daily Gralise®; days 8-14 at 1200 mg daily Gralise®). 28 day maintenance (1800 mg daily Gralise®). 7 day taper (days 1-4 at 1200 mg daily Gralise®; days 5-7 at 600 mg daily Gralise®).

DRUG

Placebo

14 day titration (days 1-7 at 600 mg daily placebo; days 8-14 at 1200 mg daily placebo). 28 day maintenance (1800 mg daily placebo). 7 day taper (days 1-4 at 1200 mg daily placebo; days 5-7 at 600 mg daily placebo).

Trial Locations (1)

14618

University of Rochester, Rochester

All Listed Sponsors
lead

University of Rochester

OTHER

NCT01764464 - GRASSP: Gralise® for Spine Surgery Pain | Biotech Hunter | Biotech Hunter